23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound[1][2][3].
体外研究 (In Vitro)
23-epi-26-Deoxyactein (DA :10 μM and 20 μM) inhibits 3T3-L1 adipogenesis through down-regulating the expression of C/ebpα, C/ebpβ, and Pparγ, which are the critical adipogenic transcription factors[1]. 23-epi-26-Deoxyactein (DA) promotes mitochondrial biogenesis in pancreatic β-cells preventing methylglyoxal-induced oxidative cell damage and protects osteoblasts against Antimycin A-induced cell damage[2]. 23-epi-26-Deoxyactein (DA) inhibits growth of the MCF7 human breast cancer cells and induces cell cycle arrest at G1 (IC50 of 21μM)[3]. 23-epi-26-Deoxyactein (0.1-1 μM) protects osteoblasts against Antimycin A-induced cell damage[4].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Differentiation Assay[1]
Cell Line:
3T3-L1 preadipocytes.
Concentration:
0-50 μM.
Incubation Time:
8 days.
Result:
10 μM DA inhibited the adipogenesis of 3T3-L1 preadipocytes mainly at the early stage of differentiation.
体内研究 (In Vivo)
23-epi-26-Deoxyactein (DA: 5 and 10 mg/kg/d) significantly lowers body weight gain, fat mass, and liver weight in HFD-fed mice. 23-epi-26-Deoxyactein (DA) also reduces insulin resistance and serum lipoprotein levels in HFD-fed mice[1]. 23-epi-26-Deoxyactein (DA) promotes adipocyte lipolysis in mice through activating the AMPK signaling and SIRT1-FOXO1 pathway[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Diet induced obesity in C57BL/6 mice[1].
Dosage:
1-10 mg/kg.
Administration:
Orally, daily for 12 weeks.
Result:
Lowered body weight gain, fat mass, and liver weight. 5 mg/kg/d DA significantly improved HFD-induced glucose intolerance.
分子量
660.83
Formula
C37H56O10
CAS 号
501938-01-8
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Jingjing Yuan, et al. Effects of 23-epi-26-deoxyactein on adipogenesis in 3T3-L1 preadipocytes and diet-induced obesity in C57BL/6 mice. Phytomedicine. 2020 Jun 5;76:153264.
[2]. Kwang Sik Suh, et al. Deoxyactein protects pancreatic β-cells against methylglyoxal-induced oxidative cell damage by the upregulation of mitochondrial biogenesis. Int J Mol Med. 2017 Aug;40(2):539-548.
[3]. Einbond, L.S., et al. Growth inhibitory activity of extracts and purified components of black cohosh on human breast cancer cells. Breast Cancer Res. Treat. 83, 221–231. Breast Cancer Res Treat. 2004 Feb;83(3):221-31.
[4]. Eun Mi Choi, et al. Deoxyactein Isolated from Cimicifuga racemosa protects osteoblastic MC3T3-E1 cells against antimycin A-induced cytotoxicity. J Appl Toxicol. 2013 Jun;33(6):488-94.
